Lilly's Pain Is Biotech's Gain After CETP Failure
This article was originally published in Scrip
The failure of Eli Lilly & Co.'s cholesterol drug evacetrapib was a major blow to the company and will likely be a hit to Merck & Co. as well, but it wasn't a loss for everyone – Amgen Inc, Regeneron Pharmaceuticals Inc and Sanofi stand to make major gains from the loss.
You may also be interested in...
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.
The biotech confirmed that a recent death during a clinical trial was not caused by its early-stage gene therapy.